published meta-analysis   sensitivity analysis   studies

anti-inflammatory therapies in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsPRINCIPLE (COLCHICINE), 2021 0.42 [0.01; 12.75] 0.42[0.01; 12.75]PRINCIPLE (COLCHICINE), 202110%289NAnot evaluable deathsdetailed resultsPRINCIPLE (COLCHICINE), 2021 0.42 [0.01; 12.75] 0.42[0.01; 12.75]PRINCIPLE (COLCHICINE), 202110%289NAnot evaluable hospitalization or deathdetailed resultsPRINCIPLE (COLCHICINE), 2021 1.29 [0.36; 4.67] 1.29[0.36; 4.67]PRINCIPLE (COLCHICINE), 202110%289NAnot evaluable hospitalizationdetailed resultsPRINCIPLE (COLCHICINE), 2021 1.73 [0.43; 7.07] 1.73[0.43; 7.07]PRINCIPLE (COLCHICINE), 202110%289NAnot evaluable recoverydetailed resultsPRINCIPLE (COLCHICINE), 2021 0.92 [0.72; 1.17] 0.92[0.72; 1.17]PRINCIPLE (COLCHICINE), 202110%2,293NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-01 01:09 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615 - roots T: 290